Biomedical subjects

J Jeljaszewicz

Publications and source records attributed to J Jeljaszewicz.

At least 19 recordsLinked to original sources

PubMed1992

Influence of 12 antibiotics on antitumor immunity in BALB/c-mice.

The effects of 7 days' chemotherapy with penicillin G, piperacillin, mezlocillin, cephalothin, cefamandole, cefotaxime, gentamicin, amikacin, streptomycin, rifampicin, doxycycline, and clindamycin on local tumor growth and metastatic lung colonization were studied in an experimental tumor model (BALB/c-mouse-sarcoma L-1). The antibiotic dosages administered to mice were calculated on a body weight basis from doses recommended for human therapy. Except for mezlocillin, piperacillin, rifampicin and doxycycline, antibiotic treatment did not significantly influence local tumor growth, lung colonization and immune functions. Whereas mezlocillin exerted positive (tumor suppressive) or negative (tumor promoting) effects depending on the chemotherapy schedule, tumor growth and spread were significantly increased independent of the timing scheme after rifampicin or doxycycline treatment. Since certain immune functions (delayed type hypersensitivity; proliferation of spleen lymphocytes) were significantly suppressed after administration of mezlocillin, rifampicin and doxycycline, a correlation between antimicrobial chemotherapy and tumor progression may be possible.

Animals↗

PubMed1992

Adjuvant properties of propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. I. Swine immunized with live attenuated Aujeszky's disease virus vaccine and experimentally infected with virulent viruses.

Forty 5-month old swine were treated with immunomodulating Propionibacterium avidum KP-40 (PA) and/or immunized with live attenuated Aujeszky's disease (AD) virus vaccine (SuivacA); 8 weeks later all animals were infected with virulent AD viruses (NIA-3). Seven of 10 swine vaccinated without PA developed mild/moderate symptoms of infection with 3- to 5-day fever and a temporary halt in weight gain. Application of PA together with the vaccine lowered the morbidity rate, shortened the period of fever and speeded recovery. Only low levels of virus-neutralizing IgG antibodies were found in vaccinated swine and application of PA did not influence antibody titers.

Adjuvants, Immunologic↗

PubMed1992

Adjuvant properties of Propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. II. Swine immunized with inactivated Haemophilus pleuropneumoniae vaccine and experimentally infected with different virulent serotypes of H. pleuropneumoniae.

Forty 3-month old swine were treated with immunomodulating Propionibacterium avidum KP-40 (PA) and/or vaccinated with a formalin-inactivated mixture of serotypes 1, 3, 5 and 9 of Haemophilus pleuropneumoniae (Pleurovac). Three weeks after revaccination all animals were inoculated with viable single serotypes of Haemophilus pleuropneumoniae. The IgG antibodies induced by vaccination agglutinated all serotypes of Haemophilus pleuropneumoniae, except for serotype 5. Antibody titers were not influenced by the application of PA together with the vaccine. Infection of vaccinated piglets resulted in the development of pleuropneumonia in 8 out of 10 animals, while vaccination together with application of PA lowered the morbidity rate to 1 out of 10 (p < 0.05). The usefulness of a PA prophylaxis was also demonstrated in non-vaccinated piglets infected with Haemophilus pleuropneumoniae. Because of the considerable variability of strains and serotypes of Haemophilus pleuropneumoniae and the generally low prophylactic potency of pleuropneumonia vaccines it is concluded that long-lasting enhancement of non-specific antiinfective resistance caused by PA may lower the risk of endemic infections in vaccinated piglets.

Actinobacillus Infections↗

PubMed1992

Adjuvant properties of Propionibacterium avidum KP-40 in vaccination against endemic viral and bacterial infections. III. Swine immunized with live attenuated Erysipelothrix rhusiopathiae vaccine and experimentally infected with virulent strains R203 and R270B of E. rhusiopathiae.

Fifty 4-month old piglets were treated with immunomodulating Propionibacterium avidum KP-40 (PA) and/or immunized with live attenuated Erysipelothrix rhusiopathiae vaccine (Orvac). Four weeks after vaccination all animals were inoculated with viable Erysipelothrix rhusipathiae. The vaccine induced the appearance of high titers of specific IgG antibodies with peak values (1:115-1:200) three weeks after immunization. Administration of PA together with the vaccine did not influence antibody titers. Analysis of the course of experimental erysipelas infection in vaccinated and/or PA-treated swine revealed the prophylactic and beneficial effects of PA. PA-treated animals showed a significantly lower lethality rate than untreated controls and the course of the disease was considerably milder, with a shorter period of fever and a faster recovery. Vaccination provided good protection of swine against the development of erysipelas and therefore, the only significant difference in animals treated with PA applied together with the vaccine was a higher gain of body mass after infection.

Adjuvants, Immunologic↗

PubMed1992

Immunotherapy of chronic active viral hepatitis B with propionibacterium granulosum KP-45 (a 5-year follow-up report).

In the period 1982 to 1984, 14 HBS-AG-positive patients with chronic active hepatitis B were treated monthly with a cell wall preparation (5 or 10 mg) of Propionibacterium granulosum KP-45 (PG), intravenously administered for a period of 6 to 10 months. All 14 patients were monitored by serological and biochemical tests as well as liver biopsy two, three and five years after completing immunotherapy with PG. During this period the patients received neither a specific antiviral, corticosteroid or interferon therapy, nor PG. Re-appearance of HBSAG or HBeAG was never seen in patients who were already free from the antigens one year after completing PG immunotherapy. During the 5-year follow-up, spontaneous improvement in serological and morphological (liver biopsy) parameters of chronic virus B hepatitis occurred in six patients. Five years after completion of PG immunotherapy, only four of the 14 patients showed trace amounts of serum HBSAG (carriers), and in two low levels of anti-HBeAG were present, while the whole group showed a decreasing tendency and serum anti-HBc was still detectable in six patients. HBeAG- and DNA-polymerase-positivity was absent in all patients. Microscopic examination of liver biopsies 5 years after PG immunotherapy showed mild symptoms of chronic hepatitis with inflammatory infiltration, non-active cirrhosis, but without massive periportal and/or multilobular necrosis and trace amounts of HBsAG and HBcAG in hepatocytes only in the four carriers. The remaining 10 patients were free of symptoms of active hepatitis and/or active cirrhosis, but all the patients had moderate to intensive fibrosis in their liver biopsies.

Adjuvants, Immunologic↗

PubMed1991

Prophylactic and therapeutic application of Propionibacterium avidum KP-40 in swine and calves with acute enzootic bronchopneumonia.

The usefulness of the prophylactic or therapeutic application of Propionibacterium avidum KP-40, a potent stimulator of the monocyte-macrophage-system, was demonstrated in piglets and calves. After a 3-month-period of observation PA-treated piglets showed a significantly improved development (decreased number of infections, gain of body weight). In piglets and calves the therapeutic use of PA together with oxytetracycline proved to be superior in the treatment of acute endemic enzootic bronchopneumonia (AEB) as compared to groups of animals receiving PA or oxytetracycline alone.

Animals↗

PubMed1990

Digestive tract microflora liberates low molecular weight peptides with immunotriggering activity.

Antibiotic digestive tract decontamination in BALB/c-mice resulted in a significant reduction of peritoneal macrophage function and lymphocyte proliferation. Considerable evidence has accumulated showing that certain species of the indigenous gastrointestinal (GI)-tract microflora, e.g. Bacteroides sp., Clostridium sp., Lactobacillus sp., and Propionibacterium sp., liberate low molecular weight peptides which are able to trigger basic immune responses. Eradication of the GI-tract microflora apparently results in a lack of peptide production correlating to immunosuppression in experimental BALB/c-mice. Substitution of peptides in GI-tract decontaminated mice reconstituted macrophage function as well as proliferation of lymphatic tissue.

Animals↗

PubMed1990

Bacteria of human physiological microflora liberate immunomodulating peptides.

Human isolates of Propionibacterium acnes and Staphylococcus saprophyticus could be shown to liberate low molecular weight peptides (MW less than 6.500 D) with immunomodulating activity. FACS analyses of BALB/c-mouse lymphoid cells from the thymus and spleen revealed an enhanced percentage of T-helper cells after peptide administration. Intestinal microflora decontamination of BALB/c-mice considerably reduced immune cell function and lymphatic tissue proliferation. Apparently, lack of peptide production or liberation correlated to immunosuppression. Substitution of peptides (from P. acnes or S. saprophyticus) to decontaminated mice reconstituted immune cell function and proliferation. Cortisone-resistant thymocytes were used as an experimental equivalent of functional cells in the thymus. Thus, cortisone treatment of BALB/c-mice significantly reduced the number of thymocytes, however, administration of microbial peptides restored the thymus population.

Adjuvants, Immunologic↗

PubMed1990

Immunomodulation by propionibacteria.

The ability of bacteria and bacterial products to modulate the immune response to unrelated antigens is well documented. Propionibacteria are amongst the most potent immunomodulators stimulating cell populations involved in nonspecific resistance. Generally, the activated immune system provides protection from infectious pathogens and malignancies via mechanisms of recognition and elimination. Accordingly, administration of propionibacteria could be shown to be of benefit in the treatment of neoplastic and infectious diseases. Thus, it can be recommended for further clinical investigations.

Adjuvants, Immunologic↗

PubMed1979

[Prospects for bacteriological studies and chemotherapy of bacterial infections].

Explore the source record for details and available documents.

Anti-Bacterial Agents↗

PubMed1979

Pseudocoagulase activity of staphylococci.

A total of 245 strains of staphylococci isolated from various pathological specimens derived from cases of human infections was tested for staphylocoagulase activity. Test systems employing normal citrated rabbit plasma and the same substrate supplemented with inhibitors of thrombin and proteolytic enzymes (but not influencing the staphylocoagulase activity) were used for testing suspensions of bacteria and cell-free culture supernatants. A total of 237 strains clotted normal rabbit plasma; however, addition of Trasylol and heparin resulted in positive results in 222 strains, whereas plasma supplemented with Trasylol and hirudin was coagulated definitely by only 173 strains. It is postulated that proteolytic enzymes of staphylococci interfere with staphylocoagulase-induced clotting and may simulate coagulase-positive activity of staphylococci. To avoid such false results, a test system for detection of staphylocoagulase should include proteolytic enzyme inhibitors. Possible mechanisms of these findings are discussed.

Animals↗

PubMed1978